Allergies News and Research

Latest Allergies News and Research

New York Times examines global fight against HIV/AIDS

Several articles in the New York Times examine the global fight against HIV/AIDS. "Uganda is the first country where major clinics routinely turn people away" because they lack funding, the newspaper writes in an article that reports "money for [HIV/AIDS] treatment has stopped growing."

11 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

10 May 2010

AllerAir supports global awareness campaign on Multiple Chemical Sensitivity Syndrome

This May, AllerAir is supporting Multiple Chemical Sensitivities and Chemical Injury Associations worldwide in their effort to spread Multiple Chemical Sensitivity Syndrome awareness

10 May 2010

House committee to investigate Johnson & Johnson after kids' Tylenol recall

A House committee is looking at Johnson & Johnson after the company announced a recall of children's medicines. "Lawmakers requested information on Thursday from regulators about Johnson & Johnson's recall of Children's Tylenol and other over-the-counter pediatric medicines, saying the company's repeated recalls 'point to a major problem' with production," Reuters/The New York Times reports.

10 May 2010

Children living near highway and railroad intersections more likely to develop asthma

Mayo Clinic researchers recently released study data showing children who lived near major highway or railroad intersections have higher diagnoses of asthma.

7 May 2010

Researchers to identify rare genetic mutation to produce histamine against TS

A single, very unusual family with Tourette syndrome has led Yale School of Medicine researchers to identify a rare mutation in a gene that is required to produce histamine. The finding provides a new framework to understand many years of data on the role of histamine function in the brain and points to a potentially novel approach to treatment of tics and Tourette.

6 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Health IT Roundup: Many obstacles, much promise

The Boston Globe: There is a lingering "professional resistance to electronic records systems that computerization advocates say threatens the goals of the new health care overhaul law. These advocates argue that using computers to track what care patients receive, for instance, is vital to deciding what medications and treatments work best."

5 May 2010

New findings show seaweed extract inhibits H1N1 virus

In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

AIDS 2010 to explore latest developments in HIV science

Organizers of the XVIII International AIDS Conference announced today that President Bill Clinton, founder of the William J. Clinton Foundation and 42nd President of the United States, and South African Health Minister Aaron Motsoaledi will be among 19 high-level speakers who will address an estimated 25,000 conference attendees in Vienna this summer.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Updated list of emergency medications and equipment for dental providers

Best practices for managing medical emergencies in dental clinics have evolved over the past decade to account for advances in knowledge and the development of new medications and medical equipment. Morton Rosenberg, DMD, of Tufts University School of Dental Medicine and an expert on dental anesthesiology, integrated existing guidelines with new information to create an updated list of emergency medications and equipment for dental providers, including an emergency preparedness checklist.

4 May 2010

ACAAI, AGA Institute announce innovative initiative to raise awareness of HAE

The American College of Allergy, Asthma and Immunology and the American Gastroenterological Association Institute today announced an innovative initiative called "HAE: Learn About It, Talk About It," at Digestive Disease Week® 2010.

4 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Researchers develop asthma medical home to care children with asthma

A comprehensive, patient-centered approach to asthma care that includes education, referrals to specialists and home visits not only improves patients' health but also has tremendous potential to decrease health care costs, according to research to be presented Saturday, May 1 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010